Streetbeat News

Regulatory

TAOP

Taoping Inc. (NASDAQ: TAOP) received a notification from Nasdaq on June 21, 2024, regarding non-compliance with the minimum bid price requirement of $1.00 per share.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:10 pm

EOLS

Evolus, Inc. (NASDAQ:EOLS) has submitted the final module of its premarket approval application to the U.S. FDA for its Evolysse™ Lift and Evolysse™ Smooth dermal filler products targeting the nasolabial fold.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:09 pm

BUJA

Bukit Jalil Global Acquisition 1 has revised the terms and conditions to amend its charter and trust agreement with the trustee of its trust account.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:08 pm

ENLV

Enlivex Therapeutics Ltd. (NASDAQ: ENLV) has dosed the first patient in a Phase I/II trial for AllocetraTM, targeting thumb osteoarthritis. This trial aims to evaluate the safety and efficacy of AllocetraTM in up to 46 patients, with no current FDA-approved therapies for this condition.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:07 pm

FDMT

4D Molecular Therapeutics (FDMT) announced that the FDA has cleared its IND application for 4D-175, a genetic medicine for treating geographic atrophy. The treatment uses a proprietary AAV vector and a codon-optimized transgene. Phase 1 clinical trial enrollment is expected to begin in H2 2024.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:04 pm

IFRX

InflaRx's GOHIBIC (Vilobelimab) has been selected by BARDA for a Phase 2 study on Acute Respiratory Distress Syndrome. The DSMB has recommended continuation without modification for the third time, with a safety review including 395 patients. An interim survival analysis is expected early 2025, and rapid enrollment positions the company for completion by Q1 2025.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:04 pm

ARGX

Argenx announced FDA approval of VYVGART Hytrulo for patients with Chronic Inflammatory Demyelinating Polyneuropathy.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 12:01 pm

ALLR

Allarity Therapeutics, Inc. (ALLR) has received a delisting notice from Nasdaq for failing to maintain a minimum bid price of $1 per share for 30 consecutive business days. The company plans to request a hearing to appeal the decision, which will temporarily stay the delisting process.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:49 am

BTCUSD

ETHUSD

GBTC

Bitcoin has dropped below $61,000, leading to $260 million in long positions being liquidated. Miners are under pressure to sell due to higher breakeven prices, and the German government has sold 3,000 BTC. Despite short-term volatility, QCP Capital is optimistic about a bullish turn towards the year-end. Ethereum shows strong bullish sentiment, partly due to expectations of an ETH spot ETF launch. Bitcoin spot ETFs have seen net outflows, but investor interest remains strong.

Portfolio Pulse from Murtuza Merchant

June 24, 2024 | 11:45 am

ARWR

Arrowhead Pharmaceuticals presented promising preclinical data on their investigational obesity treatment, ARO-INHBE, at the ADA conference. The data showed significant gene silencing and potential benefits in weight and fat reduction. Arrowhead plans to seek regulatory clearance for clinical trials in late 2024.

Portfolio Pulse from Benzinga Newsdesk

June 24, 2024 | 11:45 am